Insilico Medicine

Eli Lilly has acquired rights to Insilico Medicine’s AI-discovered drug pipeline in a $2.75 billion deal. This significant partnership highlights AI’s growing role in drug discovery. The agreement includes an upfront payment and future royalties, reflecting the innovative nature of the collaboration. Insilico, a leader in AI-driven drug discovery, has numerous candidates in clinical trials. This deal leverages Lilly’s expertise with Insilico’s AI platform, aiming to accelerate the development of new therapies and reinforce Lilly’s expansion into the Chinese market.